The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

How bad is this news for Novavax? Let's find out. Image source: Getty Images.

The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu ...

The U.S. Food and Drug Administration has put on hold a trial of Novavax's COVID-influenza and its standalone flu vaccines ...

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...

Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.